Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | SCN4A | P35499 | 5/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | ACP3 | P15309 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MC4R | P32245 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3865062 | 1.00 | ESR1 (0.46) | ESR1TSHRACHESCN4AMAOA | |
| SCHEMBL3863813 | 1.00 | ESR1 (0.46) | ESR1TSHRACHESCN4AMAOA | |
| Hydrochloric Acid SCHEMBL20238422 | 0.98 | ESR1 (0.45) | ESR1TSHRACHESCN4AMAOA | |
| Hydrochloric Acid SCHEMBL4935577 | 0.98 | ESR1 (0.45) | ESR1TSHRACHESCN4AMAOA | |
| SCHEMBL3678678 | 0.85 | TSHR (0.44) | TSHRMAOASLC6A4 | |
| SCHEMBL5147323 | 0.83 | ADRA2A (0.39) | ESR1TSHRSCN4AMAOAMAOB | |
| SCHEMBL15295186 | 0.83 | ESR1 (0.43) | ESR1TSHRACHESCN4AMAOA | |
| SCHEMBL15295134 | 0.83 | ESR1 (0.43) | ESR1TSHRACHESCN4AMAOA | |
| SCHEMBL7591099 | 0.82 | ESR1 (0.46) | ESR1TSHRACHESCN4AMAOA | |
| SCHEMBL28448173 | 0.82 | ESR1 (0.46) | ESR1TSHRACHESCN4AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118401580-A | Process for producing thermoplastic polyoxazolidinones | 科思创德国股份有限公司 | 2024-07-26 | — | — | CN | disclosed |
| CN-116529281-A | Process for producing thermoplastic polyoxazolidone polymers | 科思创德国股份有限公司 | 2023-08-01 | — | — | CN | disclosed |
| CN-115989260-A | Method for producing thermoplastic polyoxazolidinones | 科思创德国股份有限公司 | 2023-04-18 | — | — | CN | disclosed |
| CN-115989262-A | Process for producing thermoplastic polyoxazolidinones | 科思创德国股份有限公司 | 2023-04-18 | — | — | CN | disclosed |
| CN-115989261-A | Process for producing thermoplastic polyoxazolidinones | 科思创德国股份有限公司 | 2023-04-18 | — | — | CN | disclosed |
| US-20200299309-A1 | Compounds Useful in HIV Therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-09-24 | — | — | US | disclosed |
| CN-110325531-A | Benzsulfamide and its purposes as therapeutic agent | 泽农医药公司 | 2019-10-11 | — | — | CN | disclosed |
| CN-105899205-B | Progress of preventing at diabetes B method | 维瓦斯公司 | 2019-07-09 | — | — | CN | disclosed |
| CN-109862879-A | The anti-tamper preparation of ephedrine and its derivative | 格吕伦塔尔有限公司 | 2019-06-07 | — | — | CN | disclosed |
| EP-2691384-A1 | (ALPHA- SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5 -TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THESE COMPOUNDS FOR USE IN TREATING PROLIFERATIVE DISEASES | MEI Pharma, Inc. (US) | 2014-02-05 | — | — | EP | disclosed |
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | GLAXO GROUP LIMITED (GB) | 2007-05-17 | — | — | US | disclosed |
| US-20070021494-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2007-01-25 | — | — | US | disclosed |
| US-20070021494-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2007-01-25 | — | — | US | disclosed |
| EP-1454958-B1 | LACTIC ACID POLYMER COMPOSITION AND MOLDED OBJECT THEREOF | NEW JAPAN CHEM CO LTD (JP) | 2006-10-04 | — | — | EP | disclosed |
| WO-2005058892-A1 | PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-06-30 | — | — | WO | disclosed |
| US-20050001349-A1 | Lactic acid polymer composition and molded object thereof | NEW JAPAN CHEMICAL CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
| EP-1454958-A1 | LACTIC ACID POLYMER COMPOSITION AND MOLDED OBJECT THEREOF | NEW JAPAN CHEMICAL CO.,LTD. (JP) | 2004-09-08 | — | — | EP | disclosed |
| US-5973076-A | MOLDING; CONTROLLING TEMPERATURE IN PRESENCE OF AN AMIDE COMPOUND | NEW JAPAN CHEMICAL CO., LTD. (JP) | 1999-10-26 | — | — | US | disclosed |
| EP-0776933-B1 | Polybutene-1 resin composition and a method of accelerating the crystal transformation | NEW JAPAN CHEM CO LTD (JP) | 1999-08-04 | — | — | EP | disclosed |
| EP-0776933-A1 | Polybutene-1 resin composition and a method of accelerating the crystal transformation | NEW JAPAN CHEMICAL CO.,LTD. (JP) | 1997-06-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021494-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | CCR1, ACKR3, CXCR1 | ESR1 3037/4885TSHR 2257/4885ACHE 4743/4885 |
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | PDE4B, PDE3B, PDE4A | ESR1 4063/4885TSHR 1576/4885ACHE 167/4885 |
| US-20200299309-A1 | Compounds Useful in HIV Therapy | CCR5, SLC11A2, CD4 | ESR1 4250/4885TSHR 4875/4885ACHE 3741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.